Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 28,800 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Clear all
Completed Phase 1 Interventional Results available

Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

NCT01052701
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
Ribavirin, Ribavirin plus Abacavir (ABC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

NCT02201901
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
49
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

NCT00489281
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide, Fludarabine, Mycophenolate mofetil, Sirolimus, Allogeneic bone marrow transplant, Total body irradiation - 200, Levetiracetam, Anti-thymocyte globulin, Total body irradiation - 400
Drug · Procedure · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
2 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mortality Reduction After Oral Azithromycin: Mortality Study

NCT02047981
View directory record Official record
Conditions
Childhood Mortality
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month to 60 Months
Enrollment
190,238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

A Study of Galunisertib on the Immune System in Participants With Cancer

NCT02304419
View directory record Official record
Conditions
Neoplasm
Interventions
Galunisertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 3 Interventional

Lumbar Transforaminal Epidural Corticosteroid Injection(s) Versus Defined Physical Therapy

NCT01443819
View directory record Official record
Conditions
Lumbar Radiculopathy
Interventions
Lumbar Transforaminal Epidural Corticosteroid Injection, Physical Therapy, Observation
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Daly City, California • Mill Valley, California • Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

NCT00360828
View directory record Official record
Conditions
Astrocytoma, Glioma, Oligodendroglioma
Interventions
Irinotecan Hydrochloride (HCI) Treatment, Continued Irinotecan Hydrochloride (HCI) Treatment
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 23, 2026, 6:42 AM EDT
Recruiting Phase 2 Interventional

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT07393867
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional

Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

NCT01389700
View directory record Official record
Conditions
Infection Prophylaxis
Interventions
SAR279356, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 1 Interventional

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

NCT06021600
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions
Cladribine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Not listed Not applicable Interventional

Brachial Plexus Birth Palsy: Reinforcement Paradigm to Augment Recovery

NCT03886792
View directory record Official record
Conditions
Brachial Plexus Palsy
Interventions
Triggered reinforcement, Social interaction
Behavioral
Lead sponsor
Chapman University
Other
Eligibility
3 Months to 12 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 23, 2026, 6:42 AM EDT
Recruiting No phase listed Observational

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

NCT06683092
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 1 Interventional

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

NCT06540066
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
Interventions
BGB-B3227, Tislelizumab, Chemotherapy
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Los Angeles, California • St Louis, Missouri • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

NCT03048422
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

NCT06118151
View directory record Official record
Conditions
Influenza, Influenza Immunization
Interventions
Influenza Hemagglutinin mRNA vaccine, Quadrivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
20
States / cities
Rolling Hills Estates, California • San Diego, California • Coral Gables, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 23, 2026, 6:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

NCT01873131
View directory record Official record
Conditions
Hemangioma
Interventions
topical timolol maleate, Pulsed dye laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 3 Months
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 23, 2026, 6:42 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Interventions
Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

NCT07736937
View directory record Official record
Conditions
Ovarian Cancer
Interventions
TUB-040 + Carbo + BEV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Los Angeles, California • East Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Drug Interaction of ASP015K and Midazolam

NCT01182077
View directory record Official record
Conditions
Healthy, Pharmacokinetics of ASP015K and Midazolam
Interventions
ASP015K, Midazolam
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 23, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

NCT01220128
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 23, 2026, 6:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

NCT01903265
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
TNX-102 SL 2.8mg, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 23, 2026, 6:42 AM EDT
Enrolling by invitation No phase listed Observational

RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study

NCT07823465
View directory record Official record
Conditions
Focal Epilepsy, Drug-resistant Focal Epilepsy
Interventions
NeuroPace RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
13 Years to 19 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 6:42 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Zynrelef Versus Adductor Canal Block

NCT07216586
View directory record Official record
Conditions
Knee Osteoarthritis, Arthritis Knee
Interventions
ZYNRELEF 400Mg-12Mg Extended-Release Solution, Ultrasound-Guided Adductor Canal Block, Ropivacaine 0.5% Injectable Solution
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 6:42 AM EDT